Novo Nordisk: settles with Teva over diabetes drug generic
(CercleFinance.com) - Denmark's Novo Nordisk has reached a settlement with Teva Pharmaceuticals over the launch of a generic version of its diabetes drug Victoza.
Subject to certain conditions, Teva could launch a generic version of Victoza earlier, although not before March 2023, unless the Victoza patents are no longer in force or there is another generic version on the market, the company said.
If Novo Nordisk is granted six months paediatric extension for Victoza, all the timelines will be extended by six months, the Danish drugmaker said.
The financial terms of the agreement have remained confidential.
Copyright (c) 2019 CercleFinance.com. All rights reserved.
Subject to certain conditions, Teva could launch a generic version of Victoza earlier, although not before March 2023, unless the Victoza patents are no longer in force or there is another generic version on the market, the company said.
If Novo Nordisk is granted six months paediatric extension for Victoza, all the timelines will be extended by six months, the Danish drugmaker said.
The financial terms of the agreement have remained confidential.
Copyright (c) 2019 CercleFinance.com. All rights reserved.